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Cadmiumand cadmiumcompounds are contaminants of the environment, food, anddrinkingwater and are important constituents
of cigarette smoke. Cd exposure has also been associated with airborne particulate CdO and with Cd-containing quantum dots in
medical therapy. Adverse cadmium effects reported in the literature have stimulated during recent years an ongoing discussion to
better elucidate cadmiumoutcomes at cell andmolecular level.Thepresentwork is designed to gain an insight into themechanismof
p53 impairment at gene and protein level to understand Cd-induced resistance to apoptosis. We used a hepatoma cell line (HepG2)
derived from liver, known to be metal responsive. At genotoxic cadmium concentrations no cell cycle arrest was observed. The
p53 at gene and protein level was not regulated. Fluorescence images showed that p53 was correctly translocated into the nucleus
but that the p21Cip1/WAF-1, a downstream protein of p53 network involved in cell cycle regulation, was not activated at the highest
cadmium concentrations used. The miRNAs analysis revealed an upregulation of mir-372, an miRNA able to affect p21Cip1/WAF-1
expression and promote cell cycle progression and proliferation.The role of metallothioneins and possible conformational changes
of p53 are discussed.
1. Introduction
Cadmium (Cd) is a toxic element present in air, soil, sedi-
ment, and water. It is released into the environment through
the waste from heavy metal mining, manufactures of nickel-
cadmium batteries, and from other industrial and agricul-
tural activities. It is ubiquitously present in the environment
and in food, thus leading to a potential risk of human
exposure. Nonoccupational exposure is mainly from diet and
smoking, due to an accumulation of Cd in tobacco plants [1].
More recently, Cd exposure has been associatedwith airborne
particulate CdO and with Cd-containing quantum dots in
medical therapy [2, 3]. Targets of Cd toxicity include liver,
lung, kidney cortex, bone, the cardiovascular system, and the
immune system ([4], see the reviews [5–7]).
Cd and Cd compounds have been classified as human
carcinogens (Group 1) by the World Health Organization’s
International Agency for Research on Cancer [8] and by
the National Toxicology Program [9]. Although Cd carcino-
genicity has been recognized by epidemiological studies and
animal experiments, the underlying mechanisms are still
matter of research activities. Proposedmechanisms have been
recently reviewed [10, 11] and range from thiol-containing
protein affection and consequent production of reactive oxy-
gen species, and interference with essential metals. Moreover,
the deregulation of the cellular response to DNA damage
and the resistance to apoptosis are among other proposed
mechanisms involved in Cd-induced carcinogenicity [5].
The tumor suppressor protein p53 is a crucial component
of the cellular response to DNA damage, and it is primarily
involved in defensemechanisms by transcriptional activation
of genes responsible of growth arrest and apoptosis for the
elimination of heavily damaged cells. The inactivation of
p53 is one common feature found in human cancers [12].
Cd has been demonstrated to interfere with the structure
and function of p53 [5], although opposite effects have been
reported. Namely, some authors refer to the induction of the
p53-mediated stress response [13], while others demonstrated
an inactivation of p53 via structural changes [14].
In this study we focused on the p53 pathway at gene
and protein level to better investigate the involvement of
this tumor suppressor protein in Cd-induced carcinogenesis.
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A microRNA analysis was further performed to evidence
a possible role of these small and noncoding regulatory
molecules.
We used the HepG2 cells as a model of human origin
from a target organ. The HepG2 cells are able to form struc-
tures typical of normal hepatocytes, express liver-specific
functions, are metal responsive, and, more in general, are
well characterized, thus making them a useful model for
mechanistic studies on Cd carcinogenicity [15–19].
2. Materials and Methods
2.1. Cell Line and Culture Conditions. HepG2 cells were
routinely grown in a monolayer culture in the presence of
Opti-MEMmedium (Invitrogen, San GiulianoMilanese, MI,
Italy) supplemented with 10% heat inactivated fetal bovine
serum (Invitrogen) and 1% antibiotics. The cells were main-
tained in an incubator at 37∘C and humidified atmosphere
of 5% CO
2
. The medium was replaced twice a week and
the cells were trypsinized and diluted every 7 days at 1 : 3
ratio. The cells were transferred either into 165 cm2 flasks
(Costar, Euroclone, Pero, MI, Italy) for protein preparations
and cell cycle analysis, or into 8 cm2 plastic dishes (Costar)
for immunofluorescence analysis. Cells grown in complete
culture medium represented the controls. A 1mM stock
solution of CdCl
2
monohydrate 97% purity (Cd, BDH Italia,
Rome, Italy) was prepared in sterile MilliQ water (Millipore,
Vimodrone, MI, Italy), and further dilutions were prepared
in complete culture medium just before use.
2.2. Cell Cycle Analysis. The cells were seeded (7 × 105
cells/Petri dishes) and treated (10𝜇M Cd, 24, 48, and 72
hours) 24 h after seeding. Treated and control cells were har-
vested by trypsinization, collected by centrifugation (200 g,
5min), and washed in PBS. The samples were further cen-
trifuged (200 g, 5min) to remove the PBS, fixed in cold
ethanol, and stored at −20∘C until use. Defrosted samples
were centrifuged (200 g, 10min) to remove ethanol and were
incubated (15min) for RNA hydrolysis and DNA staining
using the DNA Prestain kit (Coulter Reagents, Beckman
Coulter). Cell cycle distribution was analyzed by flow cytom-
etry (Becton Dickinson Italia, Buccinasco, MI, Italy). The
percentage of cells in each phase was estimated by FlowJo
software using the Dean-Jett-Fox best fit and compared to
untreated control cells.
2.3. p53 Extraction and Immunochemical Analysis. HepG2
cells (5 × 106 cells/flask) were exposed to increasing Cd
concentrations (0.1–10𝜇M) for 24 h. At the end of the
exposure time, the cells were harvested by trypsinization,
collected by centrifugation (200 g, 10min), and washed with
PBS to remove Cd excess. The cells were collected again
by centrifugation (200 g, 10min), and homogenates of total
proteins were obtained by resuspension in sample buffer
(0.05M Tris-HCl, pH 6.8, containing 2% SDS, 10% glycerol,
10% 𝛽-mercaptoethanol) containing 1mM PMSF freshly
added prior use. Homogenates were boiled for 5min, passed
3-4 times through a syringe needle (22 ga Ø), and stored at
−80∘C until use. Total protein content was estimated by the
Lowry method [20] using BSA as a standard.
Fifty𝜇g of total proteins was separated on 10% NuPAGE
gels (Invitrogen) in MOPS running buffer (Invitrogen, cat.
number NP0001) and transferred onto a nitrocellulose mem-
brane and processed for immunochemical analysis. A p53
monoclonal antibody (StressGen, Vinci-Biochem, Vinci, FI,
Italy) was used, and the membrane incubation was run
overnight at 4∘C. After incubation with the secondary anti-
body (mouse IgG alkaline phosphatase conjugate, Sigma), the
specific bands were visualized by the colorimetric substrates
BCIP/NBT (Fast, Sigma).
2.4. p53 Immunofluorescence Localization. HepG2 cells were
plated (100.000 cells/cm2) on glass coverslips and left to
recover at 37∘C in incubator. The next day, the cells were
treated with Cd (2, and 10 𝜇M) for 24 h. After treatment,
the cells were rinsed with PBS, fixed with methanol (5min,
−20∘C), and processed for immunofluorescence labeling of
the p53 protein. Primary antibody mouse anti-p53 (Sterss-
Gen) at 1 : 50 dilution in PBS + 1% BSA was used, and the
cells were incubated for 1 h at 37∘C. After saturation with PBS
and PBS + 1% BSA, the cells were labeled with 1 : 100 Alexa
Fluor 594 (Molecular Probes, Invitrogen) and incubated for
45min at 37∘C in humidified atmosphere.Then, sampleswere
washed in PBS and distilled water, stained with DAPI (4󸀠,6-
diamidino-2-phenylindole) for nuclei visualization, and air-
dried prior mounting. The coverslips were viewed on a Zeiss
Axioplan microscope equipped with epifluorescence optics
and a digital camera (CoolSnap-ProColors Media Cybernet-
ics, Bethesda, MA, USA), and images were taken and stored
using the Image Proplus software (Media Cybernetics).
2.5. 𝑝21𝐶𝑖𝑝1/𝑊𝐴𝐹-1 Immunochemical Analysis. HepG2 homo-
genates obtained as described in par.2.4were used to evaluate
the p21Cip1/WAF-1 expression in Cd-treated cells (0.1–10 𝜇M).
Fifty𝜇g of homogenated proteins was separated by elec-
trophoresis in 12% NuPage gels (Invitrogen) and processed
as previously described [16] to enhance membrane transfer
and retention of low molecular weight proteins. Mouse anti-
p21Cip1/WAF-1 was used as a primary antibody (Invitrogen).
Anti-mouse alkaline phosphatase conjugate (Sigma, St. Louis,
MO, USA) was used as a secondary antibody, and pro-
tein binding was visualized by the colorimetric substrate
BCIP/NBT (Sigma-Aldrich, Milano Italy).
2.6. MicroRNA Expression Profiling. RNA was extracted
using the MIRVANA kit (AMBION) according to the manu-
facturer’s instructions. Concentration and quality were deter-
mined by Nanodrop. Total RNA was reverse transcribed
with Taqman MicroRNA Reverse Transcription Kit using
Megaplex RT Primers (Applied Biosystems). Real-time PCR
reactions were carried out on preconfigured microfluidic
cards (TaqmanArrayMicroRNACards, set A, V2.2 and set B,
V3, Applied Biosystems) allowing the detection of about 754
unique assays specific and four candidate endogenous control
assays.
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Two biological replicates for control and two for 10 𝜇M
Cdwere tested. Experimental data were then analyzed by SDS
2.3 software (Applied Biosystems) and the relative expression
values were calculated using as endogenous control U6 for
miRNA. MiRNAs with a threshold cycle <33 that showed
a log fold change greater than one in samples treated with
cadmium as compared to control samples were considered as
induced.
2.7. Statistical Analysis. Student’s 𝑡-test or ANOVA (multiple
range test) was used for comparisons. The software package
Statgraphics Plus version 5.0 (Statistical Graphics Corp.,
Manugistic Inc. Rockville, MD, USA) was used for the
statistical analysis.
3. Results
3.1. Cell Cycle Progression Is Not Affected by Cd Exposure
in HepG2 Cells. We previously demonstrated by MTT assay
that Cd concentrations used in the present work induce a
maximum of 20% loss of viability at 10 𝜇MCd.The IC
50
value
(50% of the reduction of cell viability) was computed to be
25.5 𝜇M [16].
Cadmium induces DNAdamage inHepG2 cells, as previ-
ously reported [22, 23], and as confirmed by our experiments
on single-strand breaks formation (data not shown).
In the presence of DNA damage (e.g., single strand
breaks), the cell systemshave evolvedmultiplemechanisms to
avoid damage propagation. Among these, responses working
inmammalian cells include the cell cycle check points control
mechanisms, as well as apoptosis for the elimination of
heavily damaged cells.
Our results showed that in HepG2 cells exposed to the
highest Cd concentration (10 𝜇M) for different time points
(24, 48, and 72 h), there was no effect on cell cycle pro-
gression. The distribution of cell population among the cell
cycle phases (G1, S, G2/M) did not change when statistically
compared to controls (Figure 1(a)), even after 72 h of Cd
exposure (Figures 1(a) and 1(b)).
3.2. p53 Expression and Localization in Cd-Stressed HepG2
Cells. The p53 tumor suppressor protein is a key regulator of
cell cycle arrest and of apoptosis. In response toDNAdamage,
the p53 is normally activated and accumulated to exert its
DNA-binding activity for the regulation of genes involved
either in G1 cell cycle arrest or apoptosis. To understand the
mechanism behind the cell cycle progression in the presence
of a genotoxic effect of Cd, we analyzed the p53 expression.
At molecular level, we focused on the genes related to the p53
signalling pathway. Interestingly, the map of KEGG shows
that the p53 gene was not regulated at the transcriptional
level (Figure 2). At protein level, immunochemical results
confirmed that there is no clear evidence of an upregulation of
this transcription factor in Cd-exposed (0.1–10 𝜇M) samples
(Figure 3).
We next analyzed the subcellular localization of p53 by
indirect immunofluorescence in the presence of genotoxic
Cd concentrations (2 and 10𝜇M) to verify whether the
p53 was correctly localized to exert its function. Fluores-
cence images showed that in control cells the p53 signal
is spread and localizes throughout the cytoplasm (Figures
4(a)–4(c)). In cells treated with DNA-damaging concen-
trations of Cd (2 and 10 𝜇M), the p53 fluorescence signal
is increasingly concentrated and accumulated in areas that
co-localize with the nuclei (Figures 4(d)–4(f) and 4(g)–
4(i)), as expected by a transcription factor. To quantitatively
express the nuclear localization of the p53, a wide population
(400–1000 cells/controls or Cd) of stained cells coming
from independent experiments and different coverslips was
counted. In controls only 10 ± 3,2% of the cells showed a
p53 nuclear localization, confirming the predominant cyto-
plasmic distribution in unstressed cells, while in Cd-treated
samples an increasing percentage of the cells showed that
the transcription factor moves into the nucleus (Cd 2 𝜇M
30 ± 9,2%, and Cd 10 𝜇M 67 ± 18%) to activate downstream
genes. The extent of p53 nuclear localization in controls and
in Cd-treated cells is summarized quantitatively in Figure 5.
3.3. 𝑝21𝐶𝑖𝑝1/𝑊𝐴𝐹-1 Levels in Cd-Stressed HepG2 Cells. To
better understand the p53 pathway and regulatory activity, we
have analyzed the expression of the p21Cip1/WAF-1 protein.The
p21Cip1/WAF-1 is a downstream protein known to be regulated
also by p53 to trigger cell cycle arrest in DNA damaged cells.
At gene level, p21Cip1/WAF-1 was upregulated, as shown by the
p53 signalling pathway (Figure 2, in red). Nevertheless, levels
of p21Cip1/WAF-1 protein were comparable to controls at the
lower Cd concentrations and decreased at 5 and 10 𝜇M Cd
(Figure 3).
3.4. miRNA Modulation. We have analyzed the modulation
of these small and noncoding molecules, acting at posttran-
scriptional level, to unravel the apparent contrast between the
p21 gene upregulation and the p21 protein downregulation at
high Cd concentrations (5 and 10𝜇M).
The effects of 10 𝜇M Cd on miRNAs were evaluated with
microfluidic cards and the focus was on the upregulated
miRNAs. In Cd-treated samples we identified two miRNAs
that were upregulated: hsa-mir-138 and hsa-mir-372.
4. Discussion
The aim of this study was to investigate the role of the
p53 tumor suppressor at gene and protein level in order to
contribute to the comprehension of the reported resistance to
apoptosis in Cd-treated cells [5]. Cadmium carcinogenicity
has been recognized by epidemiological studies and animal
experiments, as recently reviewed [6, 8]; however, the overall
mechanism is still unclear. In addition, conflicting results
concerning the effects of Cd on biological systems are present
in the literature [13, 14], possibly justified by a recently
demonstrated hormetic effect of this metal [24, 25]. Current
evidence suggests that Cd carcinogenicity is not due to
a direct genotoxic effect of this metal. Multiple indirect
mechanisms, the interference with the cell response to DNA
damage, the deregulation of cell growth, and the resistance to
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Figure 1: Effects of CdCl
2
on cell cycle distribution of HepG2 cells. HepG2 cells were cultured in the presence of 10𝜇M Cd concentration
for different time points (24, 48, and 72 h). (a) The distribution of the cell population in the different cell cycle phases of treated cells (black
bar) is always comparable to controls (grey bar) at all tested time points. In (b) an example of histogram obtained by flow cytometer analysis
is displayed; the DNA content (𝑥 axis) is plotted against the cell number (𝑦 axis). Cells from three independent experiments were analyzed.
apoptosis aremore accreditedmechanismswhich account for
Cd carcinogenicity [5, 7, 11].
In HepG2 cells and, more in general, in mammalian
cells cadmium exerts the genotoxic effect through reactive
oxygen species generation, causing DNA strand breaks and
chromosomal aberrations ([22], for a review see [5]). The
DNA damage response is rigorously coordinated by multiple
mechanisms, among which the p53 has a key role. The p53 is
essential in the regulation of the cell cycle arrest and apoptosis
for the processing of DNA damage and for restoring genomic
stability or eliminating heavily damaged cells [26]. Our
experiments demonstrated that in Cd-treated HepG2 cells,
these regulatory mechanisms were not activated. Namely, no
cell cycle arrest was induced at the highest Cd concentration
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Figure 2: Representation of the p53 signaling pathway map from KEGG. The genes identified as regulated in 10 𝜇m Cd-treated HepG2 cells
are colored in the p53 signaling pathway map. The genes in red are upregulated and those in green are downregulated. Genes identified as
regulated have a false discovery rate corrected 𝑃 value smaller than 0.05 and fold change greater than 2.
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Figure 3: Effect of CdCl
2
on p53 and p21Cip1/WAF-1 protein expres-
sion. HepG2 homogenated proteins (50 𝜇g/lane) were separated on
12% gels or 10% gels, transferred onto nitrocellulose membrane,
and probed for p21Cip1/WAF-1 or p53 protein expression, respectively.
Representative Western blots are shown. Parallel gels stained with
Coomassie Blue G250 for equal protein loading evaluation were
performed.
tested (10 𝜇M), and no p53 upregulation was observed, as
visualized at gene as well as at protein level. In response to
stress, the p53 is normally accumulated in the nucleus and
converted into an activeDNA-binding form to control several
sets of genes to prevent the proliferation of cells carrying a
DNA damage [27]. To the best of our knowledge, our results
of fluorescencemicroscopy show for the first time that the p53
was increasingly accumulated into the nucleus in Cd-treated
HepG2 cells, according to the activity of a transcription factor.
However, despite this correct localization in stressed cells,
the p53 was not able to activate the downstream signals of
cell cycle regulation and arrest to allow the DNA repair.
This data is supported by the result on the p21Cip1/WAF-1,
a p53 downstream protein responsible for the cell cycle
arrest [26]. Indeed, in our samples the p21Cip1/WAF-1 showed
levels comparable to controls or downregulated in Cd-treated
HepG2. Therefore, this lack of regulation could account for
the normal progression of the HepG2 cells into the cell cycle
phases that we observed.
The uncontrolled proliferation of DNA-damaged cells
and the acquisition of apoptotic resistance are important
steps in themalignant transformation process. In this context,
our results on the impairment of p53 pathway activity go
through this direction. HepG2 cells, albeit derived from a
human hepatoma, express a wild type and an inducible p53
activity, well documented previously [28]. However, previous
works [3, 14] suggest that this activity could be impaired
by conformational changes in the wild type p53 protein, as
demonstrated inMCF7 andA549 cells exposed to soluble and
particulate Cd compounds. The impairment of p53 activity
could also be explained by our recent findings on microRNA
(miRNA) levels in Cd-exposed HepG2 [29].ThemiRNAs are
small and noncoding RNAs which play a key role in gene
expression at the posttranscriptional level, targeting mRNAs
for cleavage or translational repression. We previously found
that a large percentage of downregulated miRNAs belong
to the let-7 family. The let-7 family is reported to have
oncosuppressor functions as it regulates processes including
cell division andDNA repair. In this regard, very interestingly
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Figure 4: Visualization of p53 localization in CdCl
2
-treated HepG2 cells. Fixed and p53 stained cells were visualized by indirect probing
with Alexa Fluor antibody. In control HepG2 (a), a spread distribution of the p53 is shown throughout the cells, while the treatment with Cd
increases the nuclear localization of the protein (d, g). (a, d, g) cells probed for p53 in controls (a), 2 𝜇M (d), and 10𝜇M (g) Cd concentrations.
(b, e, h) cells stained with DAPI for the nuclei visualization in controls (b), 2𝜇M (e), and 10 𝜇M (h) Cd concentrations. Merge is represented
in (c, f, i) images. Microscopy magnification: 400x.
it was recently described [30] that let-7a and let-7b expression
are dependent on the p53 activity. Moreover, miRNAs are
reported to have control activities on p21 at posttranscrip-
tional level [31, 32] further sustaining our data on p21
expression at gene and protein level. Indeed, we suggest that
the apparent contrast between p21Cip1/WAF-1 upregulation at
gene level and no modulation or downregulation at protein
level could be possibly explained by the posttranscriptional
activity of miRNAs. These findings support our data on the
impaired function of this transcription factor. In order to
further explain the lack of regulation of the p53 we analyzed
the miRNA expression in Cd-treated HepG2. We analysed a
panel of miRNA regulated upon stimulation of Cd, and we
identified that two were upregulated after Cd exposure: mir-
372 and mir-138, both connected to carcinogenesis [33, 34].
Wu and colleagues [32] showed that mir-372 can bind to the
3’UTR of p21Cip1/WAF-1 affecting its expression. Furthermore,
the expression of mir-372 can promote cell proliferation and
cell-cycle progression [34].This mechanism warrants further
investigation, but the work by Wu and colleagues together
with our data on mir-372 upregulation provides hints on
the involvement of miRNAs in the toxic mechanism induced
by cadmium promoting proliferation activities. The second
miRNA that we found upregulated, mir-138, was recently
described to have oncosuppressor functions and its down-
regulation was associated with head and neck squamous cell
carcinoma (HNSCC). However, while the deregulation of
miR-138 is frequently observed in HNSCC and other cancer
types, the exact role of miR-138 in tumorigenesis remains
elusive [33]. Thus further functions and regulatory activities
of this miRNA need to be deeply depicted.
Another possible mechanism that could contribute to
the impairment of p53 activity and subsequent inhibition
of the cell cycle arrest in HepG2 cells is the interference of
metallothioneins (MTs).The expression and induction of this
low molecular weight family of proteins are associated with
protection against oxidative stress, cytotoxicity, and DNA
damage. Cd is a transcriptional modulator, among others,
of MT gene expression, and this family of metal-binding
proteins appears also to play a key role in the prevention of
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Figure 5: Quantification of the p53 nuclear localization. Percentage
(mean ± SD) of HepG2 cells showing the p53 nuclear localization
in the controls and in Cd-treated cells (2 and 10 𝜇M). The mean ±
SD values of at least 3 independent samples are shown; a number
of 400 < 𝑛 < 1000 cells were counted. Significantly different from
control: ∗𝑃 < 0.5; significantly different between Cd treatments:
#
𝑃 < 0.05.
apoptosis, acting as regulators of p53 folding and activity [35].
In addition, MT null cells are more susceptible to apoptotic
death after exposure to apoptosis-inducing agents, and the
involvement of MT in controlling apoptotic mechanisms was
suggested in the past [36].MTswere also proposed as proteins
involved in the regulation of p53 stability and DNA-binding
activity, along with a protective function in Cd-induced
toxicity [37]. In HepG2 cells, MTs are strongly upregulated in
the presence of Cd, as previously demonstrated by our group.
[16, 21, 38].These data sustain the speculation of a role forMT
as negative regulators of apoptosis and of p53 activity [35].
5. Conclusions
In conclusion, as depicted and summarized in Figure 6, we
demonstrated for the first time that in HepG2 cells exposed
to Cd, the p53 was correctly moved and accumulated into
the nucleus to exert its function of transcription factor.
However, besides this correct nuclear localization, the signals
for the cell cycle arrest were not activated. In this context, the
p21Cip1/WAF-1, a p53 downstream protein and an important
mediator of cell cycle arrest, was upregulated at gene level
but not at protein level. These results could be explained by a
posttranscriptional activity by the miRNA, as demonstrated
by the upregulation of mir-372 in Cd-treated HepG2 cells,
able to affect p21Cip1/WAF-1 expression and to promote cell
proliferation. In this complex network, it seems of cru-
cial importance to further investigate the relation between
miRNA activity and p53 impairment.
The influence of Cd on p53 inactivation by conforma-
tional changes is under investigation by our group to more
Cd
p53
p21 protein 
p53
Cell cycle 
progression
Cancer
miRNA 372
p21 mRNA
Figure 6: Overview of cadmium effects. (1) Cadmium is accumu-
lated into HepG2 cells [21] and indirectly causes a genotoxic damage
[22, 23] (data not shown); (2) the p53 is visualized into the nucleus,
as expected, to exert its function of transcription factor; (3) the
p21Cip1/WAF-1 gene (p21 mRNA) is upregulated, although no protein
upregulation is observed possibly due to a posttranscriptional
regulation by miRNA-372; (4) no cell cycle arrest is observed, thus
leading to the transmission of DNA damage and ultimately to
cancer.
deeply elucidate the apoptotic resistance and the mechanism
of Cd-carcinogenicity. Our results support the hypothesis of
Cd as a double-edge sward factor [11], as it induces DNA
damage and inhibits its repair.
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